MAB-MIG

Erenumab was approved in Europe for migraine prevention in patients with ≥ 4 monthly migraine days (MMDs). In Spain, Novartis started a personalized managed access program, which allowed free access to erenumab before official reimbursement. The Spanish Neurological Society started a prospective reg...

Descripción completa

Detalles Bibliográficos
Autores: Belvís, Roberto|||0000-0002-2137-180X, Irimia, Pablo|||0000-0002-7238-0036, Pozo-Rosich, Patricia|||0000-0003-0796-4702, González-Oria, Carmen|||0000-0002-7864-6165, Cano, Antonio, Viguera, Javier|||0000-0002-1177-5990, Sánchez, Belén, Molina, Francisco, Beltrán, Isabel, Oterino, Agustín|||0000-0002-7457-9129, Cuadrado Godia, Elisa|||0000-0002-9147-875X, Gómez-Camello, Angel, Alberte-Woodward, Miguel, Jurado, Carmen, Oms, Teresa, Ezpeleta, David, de Terán, Javier Díaz, Morollón Sánchez-Mateos, Noemí|||0000-0003-4256-4210, Latorre, Germán|||0000-0003-1719-668X, Torres-Ferrús, Marta|||0000-0003-2856-4134, Alpuente, Alicia|||0000-0001-5296-9401, Lamas, Raquel, Toledano, Carlos, Leira, Rogelio|||0000-0001-7233-2053, Santos, Sonia, Sánchez del Río, Margarita|||0000-0001-7724-2890
Tipo de recurso: artículo
Fecha de publicación:2021
País:España
Institución:Universitat Autònoma de Barcelona
Repositorio:Dipòsit Digital de Documents de la UAB
Idioma:inglés
OAI Identifier:oai:ddd.uab.cat:256514
Acceso en línea:https://ddd.uab.cat/record/256514
https://dx.doi.org/urn:doi:10.1186/s10194-021-01267-x
Access Level:acceso abierto
Palabra clave:Erenumab
Migraine
Monoclonal antibody
Preventive treatment
Registry
Descripción
Sumario:Erenumab was approved in Europe for migraine prevention in patients with ≥ 4 monthly migraine days (MMDs). In Spain, Novartis started a personalized managed access program, which allowed free access to erenumab before official reimbursement. The Spanish Neurological Society started a prospective registry to evaluate real-world effectiveness and tolerability, and all Spanish headache experts were invited to participate. We present their first results. Patients fulfilled the ICHD-3 criteria for migraine and had ≥ 4 MMDs. Sociodemographic and clinical data were registered as well as MMDs, monthly headache days, MHDs, prior and concomitant preventive treatment, medication overuse headache (MOH), migraine evolution, adverse events, and patient-reported outcomes (PROs): headache impact test (HIT-6), migraine disability assessment questionnaire (MIDAS), and patient global improvement change (PGIC). A.

Similares en LA Referencia